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ABSTRACT 
Gaucher mice, created by targeted isruption of the glucocere- 
brosidase gene, are totally deficient in glucocerebrosidase nd have a 
rapidly deteriorating clinical course analogous to the most severely aG 
fected type 2 human patients. An ultrastructural study of tissues from 
these mice revealed glucocerebroside accumulation i bone marrow, 
liver, spleen, and brain. This glycolipid had a characteristic elongated 
tubular structure and was contained in lysosomes, as demonstrated 
by colocalization with both ingested carbon particles and cathepsin D. 
In the central nervous ystem (CNS), glucocerebroside was diffusely 
stored in microglia cells and in brainstem and spinal cord neurons, 
but not in neurons of the cerebellum or cerebral cortex. This rostral- 
caudal pattern of neuronal lipid storage in these Gaucher mice repli- 
cates the pattern seen in type 2 human Gaucher patients and clearly 
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demonstrates that glycosphingolipid catabolism and/or accumulation 
varies within different brain regions. Surprisingly, the cellular pathol- 
ogy of tissue from these Gaucher mice was relatively mild, and sug- 
gests that the early and rapid demise of both Gaucher mice and 
severely affected type 2 human neonates may be the result of both a 
neurotoxic metabolite, such as glucosylsphingosine, and other fac- 
tors, such as skin water barrier dysfunction secondary to the absence 
of glucocerebrosidase activity. 
Index Entries: Type 2 Gaucher mice; targeted isruption; gluco- 
cerebrosidase; glucocerebroside; lysosomes; microglia; neurons. 
INTRODUCTION 
Gaucher disease in humans and null-allele mice is caused by the 
inherited deficiency of glucocerebrosidase, the lysosomal enzyme that 
hydrolyzes the fl-glucosidic bond in glucocerebroside. The major source 
of this glycosphingolipid is the turnover of senescent white and red blood 
cell membranes. Although glucocerebroside is predominantly degraded 
within lysosomes of normal macrophages, accumulation of this lipid in 
Gaucher disease transforms macrophages throughout the reticuloendo- 
thelial system into the characteristic "Gaucher cells." The Gaucher cells 
have a relatively small eccentrically ocated nucleus, and the cytoplasm 
contains numerous irregularly shaped or branching lysosomes filled with 
twisted tubular deposits of glucocerebroside (Barranger and Ginns, 1989; 
Martin et al., 1989). 
Gaucher disease has been classified into three subtypes, type 1 (chronic, 
non-neuronopathic), type 2 (acute, neuronopathic), and type 3 (subacute, 
neuronopathic) on the basis of the presence and degree of neurologic in- 
volvement (Barranger and Ginns, 1989; Martin et al., 1989). The clinical 
manifestations encountered in type 2 Gaucher disease include failure to 
thrive, hepatosplenomegaly, and neurologic deterioration, which often 
includes the triad of strabismus, trismus, and retroflexion of the head. 
The most severely affected type 2 patients may also have ichthyotic skin 
and/or hydrops fetalis as associated symptoms (Sidransky et al., 1992). In 
brains from the few Gaucher patients with neurologic involvement that 
have been studied, perivascular Gaucher cells are found and a variable 
degree of neuronal loss is observed. Neurons with the characteristic lyso- 
somal inclusions typically observed in Gaucher cells are encountered only 
sporadically (Banker et al., 1962; Adachi et al., 1967, Conradi et al., 1984; 
Kaye et al., 1986; Hernandez and Bueno, 1973). The pathophysiologic 
mechanisms leading to the neurologic symptoms observed in these patients 
remain unknown, largely because of the rarity of severely affected type 2 
human neonates and the very limited opportunities for extensive patho- 
logical studies in these patients. 
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A Gaucher mouse line recently created by targeted isruption of the 
glucocerebrosidase gene (Tybulewicz et al., 1992) has provided arelevant 
animal model for investigation of the pathophysiologic mechanisms occur- 
ring in type 2 Gaucher disease. In the initial report we presented limited 
pathologic results on these Gaucher mice, demonstrating that the defi- 
ciency of glucocerebrosidase didresult in accumulation of glucocerebro- 
side in macrophages. The present manuscript describes the more detailed 
ultrastructural pathology in a variety of tissues, including the liver, 
spleen, bone marrow, and brain from type 2 Gaucher mice having clinical 
features characteristic of the more severely affected type 2 Gaucher 
patients. Particular attention is focused on the CNS, including frontal and 
occipital cortex, brainstem, cerebellum, and spinal cord, in an attempt to 
explain the rapid postnatal demise of these type 2 Gaucher mice and 
severely affected type 2 human neonates. 
MATERIALS AND METHODS 
The Gaucher Mouse 
A Gaucher mouse line was developed by targeted isruption of the 
mouse glucocerebrosidase gene via homologous recombination in embry- 
onic stem (ES) cells (Tybulewicz et al., 1992). The neomycin resistance 
cassette replaces part of the exons 9 and 10 and abolishes glucocerebro- 
sidase activity in the homozygous mutant mice. 
Western Blot Analyses 
Tissue samples were stored at -20~ until use. Prior to extraction, 
the tissue samples were frozen in liquid nitrogen and then crushed into a 
fine powder. The powdered tissue was resuspended in 200-250/~L of 60- 
mM potassium phosphate, pH 5.9, containing 0.1% Triton X-100, and 
sonicated three times each for 10 s (50 W, Heat Systems Ultrasonics Inc., 
Cell Disrupter Model W225R) at 4~ After sonication, the samples were 
centrifuged at 12,000g at 4~ for 5 min, and the supernatant used for 
enzyme assay and Western blot analyses. Protein concentration was deter- 
mined with the Pierce BCA reagent using the recommended protocol 
with BSA as a standard. Enzyme assay was performed using 4-methyl- 
umbelliferyl-~-D-glucopyranoside a  substrate (Beutler and Kuhl, 1970). 
Polyacrylamide g l electrophoresis was performed using precast 12% 
minigels (NOVEX, 1.0 mm thickness) at constant current of 40 ma using 
reducing, denaturing conditions. Each lane contained 36 #g of tissue. 
After electrophoretic separation, the proteins were transferred to 
Immobilon-P (Millipore, Bedford, MA) using 25 mM tris, 192 mM glycine, 
and 20 mM methanol as buffer. The membrane was briefly rinsed with 
water and incubated in a blocking solution (5% milk powder, 0.05% 
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Tween-20, PBS pH 7.2) at 37~ for 1 h. The membrane was then in- 
cubated with rabbit antibody specific for mouse glucocerebrosidase 
(diluted 1:5000 in blocking solution) for I h at 37~ washed five times for 
5 min at 37~ with PBS pH 7.2 containing 0.05% Tween-20, and finally 
incubated with goat antirabbit IgG-HRP (human serum adsorbed, Sigma, 
St. Louis, MO) at a dilution of 1:5000 in blocking solution for 30 rain at 
37~ The wash was then repeated five times each for 5 rain in PBS pH 
7.2 containing 0.05% Tween-20 at 37~ The antibody-protein conjugate 
was detected with the ECL Detection Kit (Amersham, Arlington Heights, 
IL) using the recommended protocol. After the antibody-protein signals 
were developed, the membrane was rinsed with water, and protein stan- 
dards (Nova wide range SDS-PAGE protein standards) were visualized 
with Sulforhodamine B (50 mg/L in 30% methanol, 2% acetic acid, [Molec- 
ular Probes Inc. Eugene, OR] $1307). 
Glycosphingolipid Analyses 
Liver and brain tissue from normal, heterozygous, and mutant homo- 
zygous mice were extracted with 18 v/w of 2:1 chloroform-methanol by 
sonication for 10 min at RT, followed by addition of 0.2 vol of water. After 
vortexing, samples were centrifuged for 2 min at 12,000g. A 100-uL aliquot 
of the lower phase was evaporated todryness, resuspended in 2:1 chloro- 
form-methanol, and applied to precoated silica gel-60 high-performance thin- 
layer chromatography (HPLC) plates (Merck, Darmstadt, Germany) that 
had been activated at 100~ for I h (Kundu, 1981). Development was per- 
formed with a solvent mixture of chloroform-methanol-water, 65:25:4 
(v/v/v) for 45 rain. The plates were then air dried and the glycolipids 
visualized with orcinol-ferric hloride (Bial's) reagent. 
Tissue Processing for Epon Embedding 
Liver, spleen, bone marrow, and brain from normal and homozygous 
mutant mice were fixed in 0.1M phosphate buffer (PB), pH 7.3, contain- 
ing 1% acrolein and 0.4% glutaraldehyde. After fixation for 24 h at 4~ 
the tissues were stored in 0.1M PB, containing 2% paraformaldehyde. 
Postfixation was performed according to De Bruyn and DenBreejen 
(1976). Specific areas of the brain were selected for epon embedding, i.e., 
the frontal and occipital cerebral cortex, the cerebellum, the brainstem, 
and the cervical part of the spinal cord. After epon embedding, a further 
selection was made for the red nucleus, the vestibular nucleus, and the 
facial nerve nucleus of the brainstem. Ultrathin sections were cut with a 
LKB ultratome Nova and stained with uranylacetate and lead citrate. 
Macrophage Marking 
A suspension of carbon particles (India ink) was injected intravenously 
into normal and homozygous glucocerebrosidase deficient mice seconds 
prior to sacrificing the animals. The liver was fixed as described earlier. 
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Fig. 1. (A) Western blot analysis of glucocerebrosidase in brain of normal 
(lane 1), heterozygote (lane 2), and homozygous mutant mice (lane 3). Sample 
preparation, electrophoresis, and Western blot analyses were performed as 
described in Materials and Methods. Each lane contains 36 ug of protein; (B and C) 
Thin layer chromatography of neutral glycosphingolipids from brain (B) and liver 
(C) of normal (lane 1), heterozygote (lane 2), and homozygous mutant (and 3) 
mice. The lane marked Std contains 4 ug of glucocerebroside (GL1) standard. 
lmmunocytochemistry 
Spleen from normal and affected mice was fixed and stored as 
described earlier, but no postfixation was performed. Specimens were 
embedded in Lowicryl K4M according to standard procedures. Im- 
munolabeling of cathepsin D on ultrathin sections was performed as 
previously described (Armbruster et al., 1982). Sections were stained 
with uranylacetate and lead citrate. Sections incubated with normal rabbit 
serum showed negligible labeling. 
RESULTS 
Biochemical Findings 
The type 2 Gaucher mouse described in this work was produced by 
targeted isruption of the glucocerebrosidase gene. The affected mice are 
"null mutants" of Gaucher disease, where glucocerebrosidase i  com- 
pletely deficient. This is illustrated in Fig. 1A by the absence of glucocere- 
brosidase protein in brain tissue of affected animals. Western blot 
analyses of brain and liver (not shown) from normal and heterozygous 
mice (Fig. 1A) show that the major form of crossreacting material (CRM) 
to mouse glucocerebrosidase has an apparent mol wt of 56 kDa. 
Thin Layer Chromatographic Analyses 
for Glucocerebroside 
Elevated glucocerebroside levels were demonstrated in brain (Fig. 1B) 
and liver (Fig. 1C) of homozygous mutant mice. The difference in mobility 
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of glucocerebroside from brain compared to that from liver or the standard 
is consistent with the heterogeneity n fatty acid moieties of the lipid, being 
C24 in liver or standard and C18 in brain (Svennerholm et al., 1982). No 
elevation of glucocerebroside is observed in heterozygous mice. 
Macrophages in Bone Marrow, Liver, and Spleen 
Except for the dramatic hanges observed in the skin (Sidransky et 
al., 1992) at the light-microscopic level, no definite pathological changes 
were observed. Typical Gaucher cells, easily observed in bone marrow, 
liver, and spleen of affected humans were not readily identified in the 
neonatal mouse organs. Therefore, we performed electronmicroscopy to 
obtain information about the presence and precise localization of stored 
glycolipid. The overall cellularity of the bone marrow was identical in 
normal and mutant mice. Bone marrow from both normal and mutant 
mice is shown in Fig. 2. Storage of glucocerebroside was observed only 
in macrophages from homozygous mutant mice, where the glucocerebro- 
side is deposited in elongated tubular assays that give the lipid laden 
lysosomes their characteristic irregular shape. 
In these type 2 Gaucher mice, the lysosomal accumulation of glyco- 
lipid was most obvious in the liver. A high power magnification of a 
Kupffer cell is shown in Fig. 3. The lysosomes were marked in this experi- 
ment by intravenous injection of carbon particles prior to sacrificing the 
animals. In Fig. 4, the lysosomal nature of the storage organelles i demon- 
strated by the colocalization of the lipid deposits and the lysosomal 
marker enzyme cathepsin D. The figure shows a Lowicryl K4M ultrathin 
section of the spleen from a Gaucher mouse on which immunocytochem- 
istry was performed. The gold particles marking cathepsin D were 
located along the twisted glycolipid tubules in the lysosomes in liver. The 
accumulation of lipid was seen consistently in homozygous mutant mice 
(n = 10), but never observed in macrophages from normal (n = 5) or 
heterozygous (carrier) mice (n = 2). 
Macrophages in the CNS 
Typical Gaucher cells were not observed in histological serial sections 
of the brain of glucocerebrosidase deficient mice. However, examination 
of the selected areas of the brain (n = 6; see Materials and Methods), 
revealed at the subcellular level microglia with lysosomal accumulation of
lipid in tubular arrays that was not seen in normal mice (Figs. 5A, B). 
Macrophages throughout the CNS did contain dense material, but in this 
respect he glucocerebrosidase-deficient micewere not different from the 
normal. No lipid storage was observed in either astroglia cells or oligo- 
dendrocytes. The various cell types were distinguished by morphological 
criteria. 
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Fig. 2. (,6) Ultrathin epon section of bone marrow ot homozygous mutant 
glucocerebrosidase deficient mice; (B) Stored glucocerebroside (SP) is observed 
within a lysosome (arrow). N, nucleus; M, mitochondrion; E, erythrocyte. Bar 
represents 1.0 #m in A and 0.25/~m in B. 
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Fig. 3. Ultrathin epon section of liver of homozygous mutant glucocere- 
brosidase deficient mice sacrificed after intravenous injection of carbon particles. 
The lysosomes (L) of the Kupffer cells are marked by the ingested carbon par- 
ticles (arrows) that colocalize with the stored material. G, Golgi complex; N, 
nucleus; M, mitochondrion. Bar represents 0.2 #m. 
Fig. 4. Ultrathin Lowicryl K4M section of spleen of homozygous mutant 
mice immunogold labeled for lysosomal cathepsin D. The labeled structure is an 
elongated lysosome (L). Cathepsin D is associated with the twisted tubular 
deposits, N, nucleus. Bar represents 0.2 #m. 
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Fig. 5. Ultrathin epon section of cerebellum ofnormal (A) and homozygous 
mutant mice (B). Microglia in the CNS of healthy animals do contain occasionally 
enlarged lysosomes (L) that are associated with normal function (A). Lysosomes 
(L) filled with the characteristic deposits of glucocerebroside ar  only found in 
microglia of affected animals (B). The storage material gives the lysosome the 
irregular shape of a network spreading throughout the cytoplasm. N, nucleus. 
Bar represents 0.5 #m in A and B. 
Neurons 
Lipid storage was not detected at the light-microscopic level in neurons 
in brainstem, cerebellum, or spinal cord, and hence electronmicroscopic 
studies were performed. In brainstem of mutant mice (n = 2), glucocere- 
broside was seen within eurons of the red nucleus (Fig. 6A) and the ves- 
tibular nucleus (Fig. 6B) but not in the neurons of the facial nerve nucleus 
(Fig. 6C). Lysosomal storage was also observed in both sensory and motor 
neurons of the spinal cord (n = 2) (Fig. 7), but not in the cerebellum or the 
occipital and frontal cerebral cortex (n = 3, data not shown). 
DISCUSSION 
The ultrastructural pathology of the type 2 Gaucher mouse was 
studied in an attempt to explain the rapid postnatal death of these mice 
and severely affected type 2 neonates. The cellular and tissue pathology 
Molecular and Chemical Neuropathology Vol. 24, 1995 
188 Willernsen et al. 
Fig. 6. Ultrathin epon section of brainstem ofhomozygous mutant mice. 
Neurons of the red nucleus (A) and vestibular nucleus (B) have lysosomes (L) 
with storage material, but lysosomal storage was not observed in neurons of the 
facial nerve nucleus (C). M, mitochondrion; G, Golgi complex; N, nucleus. Bar 
represents 0.2/~m in A, B, and C. 
was remarkably mild, despite the complete deficiency of glucocerebro- 
sidase. Although the overall architecture of the liver, bone marrow, 
spleen, and brain appeared appropriate for age as judged by light micro- 
scopy, accumulation of glucocerebroside was clearly demonstrated by 
electronmicroscopy. The stored lipid in macrophages of the liver and 
spleen had the characteristic elongated tubular structure (Lee et al., 1973; 
Lee, 1982; Willemsen et al., 1988) and was contained in organelles identi- 
fied as lysosomes by the presence of ingested carbon particles and lyso- 
somal cathepsin D. Interestingly, even though these storage vacuoles 
occasionally did occupy significant cellular volume, typical Gaucher cells 
were not observed by light microscopy. 
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Fig. 7. Ultrathin epon sections of sensory (A) and motor (B) neurons in the 
spinal cord of homozygous mutant mice. The arrows indicate the array of lipid 
tubules present in the lysosomes (L). G, Golgi complex; N, nucleus. Bar 
represents 0.2/~m in A and B. 
The cellular pathology in the CNS of the homozygous mutant mice 
similarly is surprisingly limited, particularly in light of the rapid clinical 
deterioration that occurs. Glucocerebroside is stored predominantly in
microglia cells and only to a very limited extent in neurons. Although cer- 
tain sensory and motor neurons of the brainstem and spinal cord were 
affected, Purkinje cells and neurons of the cerebellar and cerebral cortex 
were free of storage product. This rostral-caudal pattern of neuronal lipid 
storage suggests that glycosphingolipid catabolism and/or accumulation 
varies between eurons in different brain regions. 
A comparison of the neuropathology of the glucocerebrosidase-deficient 
mouse with the human type 2 and 3 patients uggests that in the Gaucher 
patients there is also more deposition of glucocerebroside in microglia than 
in neurons (Banker et al., 1962; Adachi et al., 1967; Conradi et al., 1984; 
Kaye et al., 1986). The limited number of neuropathology studies in 
Gaucher patients consistently demonstrate hat Gaucher cells are predom- 
inantly located in the adventitia of vessels in the cerebral and cerebellar 
subcortical white matter, but the reported involvement of microglia and 
neurons in the different regions of the brain is more varied. An increasing 
gradient of Gaucher cells was observed from frontal to occipital cerebral 
cortex by Kaye et al. (1986), whereas Banker et al. (1962) report a compar- 
able density of Gaucher cells in the frontal, temporal, parietal, and occipital 
cortex. A similar comparison could not be made in the mouse model 
because of the lack of histologically detectable Gaucher cells. Neuronal 
storage was only sporadically found in humans throughout the CNS, 
albeit with an increasing radient from rostral to caudal, as in the Gaucher 
mice (Banker et al., 1962; Adachi et al., 1967; Hernandez and Bueno, 1973; 
Conradi, 1984). 
The degree of neuronal loss and neuronophagia in humans varied in 
different nuclei (Banker et al., 1962; Adachi et al., 1967; Hernandez and 
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Bueno, 1973; Conradi et al., 1984; Kaye et al., 1986). No such dramatic 
pathological changes were observed in the mouse. 
This Gaucher mouse line with a complete deficiency of glucocerebro- 
sidase, provides us with a relevant animal model of the most severe neo- 
natal form of Gaucher disease in which we can conveniently study the 
clinical-pathological progression ofthis disease. From the studies reported 
here, we conclude that the early demise of affected mice is probably not 
caused by liver, spleen, or bone marrow dysfunction, nor by neuronal 
degeneration, unless the observed amount of lysosomal glucocerebroside 
accumulation results in neuronal dysfunction before gross cellular pathol- 
ogy occurs. Nilsson and Svennerholm have suggested that the neurotoxin 
glucosylsphingosine (glucosylpsychosine) is elevated in the nervous ys- 
tem of type 2 patients (Nilsson and Svennerholm, 1982). Hannun and Bell 
(1987) have recently reported that lysophinogolipids, including glucosyl- 
sphingosine, are potent inhibitors of both protein kinase C activity and 
phorboldiester binding, suggesting that these sphingolipid erivatives can 
interfere with signal transduction and cellular differentiation (Ballou, 
1992; Zeller and Marchase, 1992) and thus disrupt neuronal function. 
The unusual skin texture, turgor, and lipid composition of type 2 
Gaucher skin (Sidransky et al., 1992; Tybulewicz et al., 1992; Holleran et 
al., 1993b) may also be an important factor contributing tothe rapid deteri- 
oration observed in severely affected mice and human eonates. Ceramides 
are critical components in skin permeability barrier homeostasis 
(Holleran et al., 1993b), and the functional disruption of the skin barrier 
as a consequence of the absence of glucocerebrosidase could result in 
fluid or electrolyte imbalance (Holleran et al., 1993a,b; Holleran et al., 
1994). Lastly, the homozygous mutant mice are rapidly identified by their 
mothers and are ejected from the nest. Thus they have been poorly fed, 
and, as a consequence, dehydration and hypoglycemia, may further 
hasten their demise. 
The opportunity to perform further biochemical and pathological 
studies using this mouse model of type 2 Gaucher disease should further 
our understanding of the basis of neurologic involvement observed in 
these Gaucher mice and type 2 infants. Investigations u ing these mice 
may also provide more details of the pathophysiologic mechanisms of
systemic involvement seen in Gaucher disease and permit the more 
rational development of successful therapeutic nterventions. 
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